A share price of Rhythm Pharmaceuticals Inc [RYTM] is currently trading at $63.87, up 4.28%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RYTM shares have gain 12.47% over the last week, with a monthly amount glided 5.61%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] stock has seen the most recent analyst activity on April 07, 2025, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $63 for it. On January 02, 2025, Jefferies initiated with a Buy rating and assigned a price target of $80 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $76 on December 20, 2024. Guggenheim initiated its recommendation with a Buy and recommended $70 as its price target on October 21, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on September 18, 2024, and assigned it a price target of $64. In a note dated September 17, 2024, JMP Securities initiated an Mkt Outperform rating and provided a target price of $64 on this stock.
Rhythm Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $35.17 and $68.58. Currently, Wall Street analysts expect the stock to reach $73.5 within the next 12 months. Rhythm Pharmaceuticals Inc [NASDAQ: RYTM] shares were valued at $63.87 at the most recent close of the market. An investor can expect a potential return of 15.08% based on the average RYTM price forecast.
Analyzing the RYTM fundamentals
Trailing Twelve Months sales for Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] were 136.86M which represents 25.94% growth. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -1.26%, Pretax Profit Margin comes in at -1.23%, and Net Profit Margin reading is -1.24%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -1.8 and Total Capital is -0.63. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Rhythm Pharmaceuticals Inc [NASDAQ:RYTM] is 3.30. Further, the Quick Ratio stands at 3.13, while the Cash Ratio is 0.95. Considering the valuation of this stock, the price to sales ratio is 29.69, the price to book ratio is 214.04.
Transactions by insiders
Recent insider trading involved Cramer Pamela J., Chief Human Resources Officer, that happened on Apr 29 ’25 when 7031.0 shares were sold. EVP, Head of International, Mazabraud Yann completed a deal on Apr 29 ’25 to sell 6745.0 shares. Meanwhile, Officer YANN MAZZABRAUD bought 6745.0 shares on Apr 29 ’25.
